Educational protocol hub
Ecnoglutide (XW003): protocol variants and reconstitution resources
Educational hub for Ecnoglutide (XW003), grouping 1 available protocol variant with links to the exact dosage and reconstitution pages.
What this hub covers
This page groups the available Ecnoglutide (XW003) protocol variants so readers can choose the exact vial-size guide without mixing formats.
Reconstitution workflow
Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.
Research-only context
All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.
Available protocol variants
Choose the exact guide you want to view.
Ecnoglutide (XW003)
Ecnoglutide (XW003, Hangzhou Sciwind Biosciences) is a **long-acting, cAMP-biased GLP-1 receptor agonist** in clinical development. It is not approved by the FDA or EMA and has no regulatory approval. This page summarizes published Phase 1–3 evidence and laboratory reference calculations for a hypothetical 5 mg vial.
View protocolRelated research resources
Internal links that help readers and search engines understand this peptide topic cluster.
References
- The Lancet Diabetes & Endocrinology (2025) — Phase 3 NCT05813795 ‚Äî ecnoglutide in adults with overweight or obesity without diabetes
View Source - Nature Communications (2024) — Phase 2 ‚Äî ecnoglutide in adults with type 2 diabetes
View Source - Molecular Metabolism (2023) — Phase 1 NCT04389775 ‚Äî discovery and clinical evaluation of cAMP-biased XW003
View Source - ClinicalTrials.gov — Phase 3 obstructive sleep apnoea ‚Äî NCT07387094
View Source - ClinicalTrials.gov — Phase 1b/2a oral tablet formulation ‚Äî NCT07243171
View Source - ClinicalTrials.gov — Phase 2b weekly oral VRB-101 ‚Äî NCT07281937
View Source
Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.